Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB

Since the first approval of a protein kinase inhibitor (PKI) by the Food and Drug Administration (FDA) in 2001, 55 new PKIs have reached the market, and many inhibitors are currently being evaluated in clinical trials. This is a clear indication that protein kinases still represent major drug target...

Descripción completa

Detalles Bibliográficos
Autores principales: Bournez, Colin, Carles, Fabrice, Peyrat, Gautier, Aci-Sèche, Samia, Bourg, Stéphane, Meyer, Christophe, Bonnet, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397241/
https://www.ncbi.nlm.nih.gov/pubmed/32679723
http://dx.doi.org/10.3390/molecules25143226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397241/
https://www.ncbi.nlm.nih.gov/pubmed/32679723
http://dx.doi.org/10.3390/molecules25143226

Ejemplares similares